Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.

Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM.

Oncotarget. 2012 Dec;3(12):1615-28.

2.

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.

Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W.

J Hematol Oncol. 2013 Feb 18;6:18. doi: 10.1186/1756-8722-6-18.

3.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007.

PMID:
26188279
4.

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.

Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305.

PMID:
25322685
5.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

6.

Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.

Mise J, Dembitz V, Banfic H, Visnjic D.

Pathol Oncol Res. 2011 Sep;17(3):645-56. doi: 10.1007/s12253-011-9365-z.

PMID:
21336564
7.

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.

Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM.

Oncotarget. 2014 Oct 30;5(20):10034-47.

8.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.

Oncotarget. 2010 Jun;1(2):89-103. Review.

9.

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.

Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M.

Oncotarget. 2015 Nov 10;6(35):37930-47. doi: 10.18632/oncotarget.6122.

10.

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P.

Oncotarget. 2012 Dec;3(12):1588-99.

11.

Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.

Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Jan 17;9:575-601. doi: 10.2147/DDDT.S75221.

12.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013.

PMID:
22285225
13.

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF.

Drug Des Devel Ther. 2015 Jan 14;9:487-508. doi: 10.2147/DDDT.S74127.

14.

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, Capitani S.

Leukemia. 2014 Apr;28(4):739-48. doi: 10.1038/leu.2013.226.

PMID:
23892718
15.

Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.

Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M.

Mol Cancer Ther. 2014 Jul;13(7):1848-59. doi: 10.1158/1535-7163.MCT-13-0576.

16.
17.

Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1687-95. doi: 10.1016/j.bbmt.2014.08.003.

18.

Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.

Watanabe T, Sato A, Kobayashi-Watanabe N, Sueoka-Aragane N, Kimura S, Sueoka E.

Anticancer Res. 2016 Jan;36(1):95-102.

PMID:
26722032
19.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89.

20.

Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.

Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA.

Exp Hematol. 2011 Apr;39(4):457-472.e3. doi: 10.1016/j.exphem.2011.01.005.

PMID:
21277936
Items per page

Supplemental Content

Support Center